- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Chitra Lal: Low Threshold Screening Needed for OSA
Chitra Lal, MD, D-ABSM, FCCP, FAASM, FACP, ATSF, professor of medicine at Medical University of South Carolina, says that the screening threshold for obstructive sleep apnea (OSA) should be low because 70% to 75% of patients with mild cognitive impairment have sleep apnea.
Screening for obstructive sleep apnea (OSA) early and treating it aggressively may help reduce the risk of mild cognitive impairment, says Chitra Lal, MD, D-ABSM, FCCP, FAASM, FACP, ATSF, professor of medicine at Medical University of South Carolina, in this interview from the 2023 American Thoracic Society (ATS) International Conference.
Transcript
What are some of the challenges associated with treating patients with OSA and Alzheimer disease and what do you think more providers should know about this population?
I think it's important to recognize that sleep apnea is a modifiable risk factor for mild cognitive impairment and Alzheimer disease, and therefore recognizing it early and treating it aggressively would be the key. Providers should have a low threshold for screening for sleep apnea in this patient population because there are studies which have shown that at least 70% to 75% of patients with mild cognitive impairment are proven to have sleep apnea. So, I think diagnosing it early and treating it aggressively is extremely important.
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More
